State drug controllers get power to issue NOCs for drugs meant for export

To promote ease of doing business, the DCGI has discontinued the earlier practice of such NoCs being granted by the Central Drugs Standard Control Organisation

Image via Shutterstock
<a href="http://www.shutterstock.com/pic-228848833/stock-photo-pills-drug.html" target="_blank">Image</a> via Shutterstock
BS Reporter Hyderabad
Last Updated : Aug 03 2018 | 7:35 PM IST
State drug controllers have been given complete jurisdiction to issue no objection certificates (NOCs) for the manufacture of unapproved, banned or new drugs that are solely meant for exports.    

The Drug Control General of India (DCGI) has discontinued the earlier practice wherein the grant of such NoCs was being overseen by the Central Drugs Standard Control Organisation (CDSCO). This order will come into effect from August 20, 2018.  

The Pharmaceutical Export Promotion Council of India (Pharmexcil) had recently approached the drug regulator seeking a waiver on bioequivalence (BE) studies for granting a license to the oral dosage form of drugs specified under BCS category 2 and 4 for the purpose of export.

ALSO READ: Indian pharma firms see fall in rate of final product approvals from USFDA   

Drug controllers in some states were insisting on submission of results of BE studies endorsed by the CDSO for grant of the license to manufacture such drugs for export purpose and this had been causing difficulties to exporters, according to Pharmexcil.

"In order to streamline the process and facilitate the ease of doing business, it has been decided that the process of grant of such NOCs by the CDSCO shall be discontinued and such NOCs shall be granted by the state licensing authorities themselves," the DCGI stated in a communication sent to all states and Union Territory drug controllers on August 2.


The drug controller, however, laid down certain guidelines for grant of such licenses to ensure that these products are strictly utilised for the purpose of export.    

In case of drugs covered under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985, the applicant will have to obtain NOC from the Narcotic Commissioner of India, according to the latest orders.    

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story